Gujarat Kidney & Super Speciality Ltd (GKSL) — shareholding pattern, promoter holding, financials and share price
About Gujarat Kidney & Super Speciality Ltd (GKSL)
Gujarat Kidney & Super Speciality Ltd operates in the Hospital industry, within the Healthcare sector. It trades on the NSE as GKSL and on the BSE under scrip code 544666. Its ISIN is INE0V0W01025.
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited specializes in providing multispeciality healthcare services. [1]
Listed peers in Hospital: Unihealth Hospitals Ltd, GPT Healthcare Ltd, KRM Ayurveda Ltd, Asarfi Hospital Ltd, Hannah Joseph Hospital Ltd, Lotus Eye Hospital & Institute Ltd.
Valuation & Returns
10 Jul 2026At ₹133.15 a share on 10 Jul 2026, Gujarat Kidney & Super Speciality Ltd (GKSL) was valued at a price-to-earnings ratio of 62.41x against an industry P/E of 61.73x and a price-to-book of 40.48x on a book value of ₹3.29 per share as of Mar 2025. Solomo computes return on equity of 64.85% and return on capital employed of 67.51% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 62.41x
- Industry P/E
- 61.73x
- P/B
- 40.48x
- EPS (TTM)
- ₹2.13
- Book value / share
- ₹3.29
- ROE
- 64.85%
- ROCE
- 67.51%
- ROA
- 30.39%
- Debt / equity
- 0.32x
- Dividend yield
- 0%
- EBITDA margin
- 33.91%
- 52-week range
- ₹98.25 – ₹148.45
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Gujarat Kidney & Super Speciality Ltd (GKSL) reported revenue of ₹82 crore, net profit of ₹17 crore and earnings per share of ₹1.97. That compares with revenue of ₹40 crore and net profit of ₹10 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹30.58 crore and net profit ₹4.82 crore (consolidated).
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue (₹ cr) | 0 | 5 | 40 | 82 |
| Net profit (₹ cr) | 0 | 2 | 10 | 17 |
| EPS (₹) | -0.5 | 85.5 | 1.66 | 1.97 |
| Measure | 1Y |
|---|---|
| Sales growth | 743.61% |
| Profit growth | 455.56% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 71.45% of Gujarat Kidney & Super Speciality Ltd (GKSL) (unchanged from the previous quarter), foreign institutional investors (FII) hold 4.88% and domestic institutional investors (DII) hold 0.56%. Market capitalisation was ₹1,050 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2025.
Largest disclosed public shareholders in Jun 2026: Craft Emerging Market Fund Pcc-Citadel Capital Fund 1.67%, Khandelwal Finance Private Limited 1.67%, LLP 1.6%, HUF 1.38%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 71.45% | - | 4.88% | 0.56% | 28.55% |
| Mar 2026 | 71.45% | - | 4.88% | 0.56% | 28.55% |
| Dec 2025 | 71.45% | - | 10.47% | 1.67% | 28.55% |